Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.68 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.68 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | DRD4 | P21917 | 4/20 | 0.69 |
| ▸ | DRD2 | P14416 | 7/20 | 0.68 |
| ▸ | DRD3 | P35462 | 6/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.68 |
| ▸ | DRD1 | P21728 | 3/20 | 0.68 |
| ▸ | DRD5 | P21918 | 3/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031666 | 0.98 | MAPT (1.00) | MAPTDRD4DRD2DRD3HTR1A | |
| SCHEMBL6030916 | 0.90 | MAPT (0.83) | MAPTDRD4DRD2DRD3DRD5 | |
| Hydrochloric Acid SCHEMBL6030550 | 0.88 | MAPT (0.81) | MAPTDRD4DRD2DRD3DRD5 | |
| SCHEMBL5988539 | 0.85 | MAPT (0.77) | MAPTDRD4DRD2DRD3HTR1A | |
| SCHEMBL7167971 | 0.85 | MAPT (0.76) | MAPTDRD4DRD2DRD3HTR1A | |
| SCHEMBL7991840 | 0.84 | DRD2 (0.82) | MAPTDRD4DRD2DRD3HTR1A | |
| SCHEMBL6698551 | 0.84 | MAPT (0.74) | MAPTDRD4DRD2DRD3HTR1A | |
| Bromide SCHEMBL6031230 | 0.84 | MAPT (0.69) | MAPTDRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL18177894 | 0.84 | MAPT (0.74) | MAPTDRD4DRD2DRD3KMT2A | |
| SCHEMBL5544112 | 0.84 | MAPT (0.74) | MAPTDRD4DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | disclosed |
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040083447-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-04-29 | — | — | US | disclosed |
| US-6656943-B2 | In the treatment or prevention of psychotic disorders such as schizophrenia psychotic depression, mania and other central nervous system diseases | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | disclosed |
| US-6172229-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5859246-A | TREATING NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | DRD2, DRD4, HTR2C | HTR1A 6/4885SIGMAR1 96/4885SLC6A2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.